Recombinant Capital & International Biomedicine Management Partners Present
ALLICENSE 2000:
BUILDING A GLOBAL PHARMACEUTICAL PERSPECTIVE
May 3 & 4, 2000
Messe Basel, Switzerland

Agenda
(As of April 27, 2000)

All speakers confirmed



Wednesday, May 3

08:00 to 08:45
Keynote Address: How Can We Strengthen European Science?

· Dr. Gottfried Schatz, President, Swiss Science and Technology Council

08:45 to 09:15
Keynote Address: Drug Discovery Tools – Surfing the Tide or Avoiding the Tsunami?

· Dr. Maria Freire, Director, Office of Technology Transfer, National Institutes of Health

09:15 to 10:00
Keynote Address: The New Drug Discovery Paradigm – Any Questions?

· Prof. Jürgen Drews, Chairman, International Biomedicine Management Partners

Morning Break 10:00 to 10:30

10:30 to 12:00
Integration of Drug Discovery Tools into Pharmaceutical R&D:

· Session Chair: Dr. Al Gray, Managing Director, Recombinant Capital Europe AG

· Dr. Patrick Gage, President, Wyeth-Ayerst Research

· Dr. George A. Scangos, Chief Executive Officer, Exelixis, Inc.

· Wendell Wierenga, Ph.D., Senior Vice President, Worldwide Pharmaceutical Sciences, Technologies and Development, Parke-Davis Pharmaceutical Research

Lunch 12:00 to 13:30

13:30 to 15:30
A Roundtable Discussion – Making Novel Discovery Tools Work Together:

· Session Chair: Mark Edwards, Managing Director, Recombinant Capital, Inc.

· Dr. Karsten Henco, Chief Executive Officer, EVOTEC BioSystems AG

· Dr. Stephen A. Hill, Chief Executive Officer, ArQule, Inc.

· Dr. Keith James, Vice President, Medicinals, Pfizer Central Research

· Dr. Friedrich von Bohlen, Chief Executive Officer, LION Bioscience AG

· Dr. Michael M. Wick, Chief Executive Officer, Telik, Inc.

Afternoon Break 15:30 to 16:00

16:00 to 17:30
Maximizing the Value of Innovative New Products:

· Session Chair: Mark Edwards, Managing Director, Recombinant Capital, Inc.

· Chris A. Rallis, President and Chief Operating Officer, Triangle Pharmaceuticals, Inc.

· Daniel K. Spiegelman, Senior Vice President & Chief Financial Officer, CV Therapeutics, Inc.

· Hollings Renton, Chief Executive Officer, Onyx Pharmaceuticals, Inc.

Thursday, May 4

08:00 to 08:45
Keynote Address: Creating Value from Terabytes of Data

· Jerry Karabelas, Ph.D., Chief Executive Officer, Novartis Pharmaceuticals

08:45 to 09:15
Keynote Address: Building Global Pharma R&D with Alliances

· Dr. Goran Ando, President, Research & Development, Pharmacia & Upjohn

09:15 to 10:00
Keynote Address: Finding Synergies in the Life Sciences Company

· Dr. Frank L. Douglas, Executive Vice President & Head, Product Innovation, Aventis

Morning Break 10:00 to 10:30

10:30 to 12:30
Harnessing Genomics to Reinvent Pharmaceutical R&D:

· Session Chair: Dr. Stefan Ryser, Chief Executive Officer, International Biomedicine Management Partners

· Dr. Bruce L. A. Carter, Chief Science Officer, Novo Nordisk & President, ZymoGenetics

· Dr. William A. Haseltine, Chief Executive Officer, Human Genome Sciences

· Steve Holtzman, Chief Business Officer, Millennium Pharmaceuticals, Inc.

· Susan E. Siegel, President, Affymetrix, Inc.


Lunch 12:30 to 13:30

13:30 to 14:15
Keynote Address: The Role of Alliances in Strengthening Innovation at Bayer

· Dr. David Ebsworth, Head, Pharmaceutical Business Group, Bayer AG

14:15 to 15:45
Consolidation in the Pharma Industry – Will it Change the Configuration of the Biotech Industry?

· Session Chair: Stelios Papadopoulos, Ph.D., Managing Director, S G Cowen Securities Corporation

· John Groom, President & Chief Operating Officer, Elan Pharmaceuticals

· Tamar Howson, Senior Vice President & Director, Business Development, SmithKline Beecham

· Prof. Dr. Peter Stadler, Chief Executive Officer, Artemis Pharmaceuticals GmbH


Afternoon Break 15:45 to 16:00

16:00 to 17:30
Managing Successful Alliance Portfolios:

· Session Chair: Mark Edwards, Managing Director, Recombinant Capital, Inc.

· Michael Ashton, Chief Executive Officer, SkyePharma Group

· Dr. Russell J. Howard, Chief Executive Officer, Maxygen

· Dr. Ronald A. Pepin, Executive Director, External Science & Technology, Bristol-Myers Squibb

· Dr. Robert Reed, President, Axys Advanced Technologies

Cocktail Party Reception 17:30 to 18:30